Our data suggest that a subset of innate B-1 cells, identified by classical markers (Bhlhe41, Cd43, and IgM) and context-specific markers (Cxcr3 and Itgb1), can contribute to autoimmunity in BOS, and thus represent potential therapeutic value. This evidence concerns the gene SPN and Autoimmunity.